Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
Lung cancer is the uncontrollable abnormal growth of cells initiating with lungs, usually in the layers of cells that allows the air passage. The abnormal cell does not obey the natural cell cycles, they get divide and redivide quickly and forms tumour. The formed tumour affect the healthy tissues and grow large enough to hinder breathing. It can spread beyond lugs through blood stream and can affects parts like lymph node, tissues and other organs. The lung cancer is secondarily most common cancer in both men and women and it is chief cause of death worldwide. Mostly cases are considered by adoption of genetic mutation in DNA that activate the uncontrolled growth of cells or inhibit their natural death.
The Asia Pacific lung cancer diagnosis market is observing lucrative growth during forecast period of 2021 to 2027. The lung cancer is becoming the significant health hazard in Asia Pacific. Lung cancer is the primary cause of cancer deaths in Asia Pacific regions. The major factors such as rising number of smokers day by day is propelling growth of Asia Pacific lung cancer diagnosis market. The rising funding in research and development activities is bosting growth of Asia Pacific lung cancer diagnosis market. However, high cost of diagnostic tests is restraining growth of Asia Pacific lung cancer diagnosis market.
The exclusive COVID-19 impact analysis report by Axiom MRC provides a 3600 analysis of micro and macro-economic factors on the lung cancer diagnostic market. In addition, complete analysis of changes on lung cancer diagnostic expenditure, economic and international policies on supply and demand side. The report also studies the impact of pandemic on Asia Pacific economies, international trade, business investments, GDP and marketing strategies of key players present in the market. The COVID-19 has almost affected every market is healthcare industries positively or negatively. The lung cancer diagnostic market is also experienced somewhat negative impact of COVID-19. As due to lockdown, physicians where treating only emergency cases whereby the other diagnostic procedure where postponed. The lung cancer patients are at higher risk of COVID-19 infections. After the slight relaxation the market is growing at significant rates. The market is get resumed with use of mask and maintaining social distancing as per the government guidelines.
The Asia Pacific lung cancer diagnostic is categorised by cancer type, diagnostic test, end user and country.
Cancer type such as small cell lung cancer and non-small cell lung cancer is comprised in the Asia Pacific lung cancer diagnostic market. In which non-small cell lung cancer is also contributing to the growth of Asia Pacific lung cancer diagnostic market. The small cell lung cancer is aggressive form of lung cancer highly associated with cigarette smoking and has tendency for early distribution. Commonly patients are symptomatic and imaging unfolds the hilar mass. Most of diagnosis of lung cancers are done with the help of biopsy carried out by pathologists. Genomic summarizing of small cell lung cancer shows the higher chromosomal rearrangements and high DNA mutations.
Diagnostic test like biomarkers test, imaging test, biopsy and other test are comprised in the Asia Pacific lung cancer diagnosis market. The biomarkers test is sub-categorised into the CA test, HER2 Test, ALK Test, Angiogenesis Inhibitors, KRAS mutation test. Likewise, Imaging test is also sub-segmented into computed tomography scan, positron emission tomography scan and chest x-ray. The biopsy sub-segmented into needle biopsy, bronchoscopy biopsy and open biopsy. The biomarkers segment is estimated to dominate the market in 2020. The growing adoption of mutation test is boosting growth of Asia Pacific lung cancer diagnostic market. The growing cases of lung cancer is also propelling growth of Asia Pacific lung cancer diagnosis market.
End user such as hospital assisted labs, independent diagnostic laboratories and cancer research institutes are comprised in the Asia Pacific lung cancer diagnostic market. In which hospital assisted labs is estimated to dominate the market in 2020. The rising early diagnosis of cancers is propelling growth of Asia Pacific lung cancer diagnostic market. The growing outflow of patients in hospital assisted labs is also boosting growth of Asia Pacific lung cancer diagnostic market.
The Asia Pacific lung cancer diagnostic market is studied for key countries such as China, India, Japan, Australia and South Korea. In which China followed by India and Japan are anticipated to dominate the market in 2020. The developing healthcare infrastructure is propelling growth of Asia Pacific lung cancer diagnostic market. The rising number of early smokers is also boosting growth of Asia Pacific lung cancer diagnostic market.
The major key players operating in the lung cancer diagnostic market are Illumina Inc., Abbott, Thermo Fisher Scientific Inc., Qiagen, Quest Diagnostics Incorporated, Neogenomics, Nanostring Technologies Inc, Myriad Genetics Inc, Roche Holding Ag, Danaher, Agilent Technologies, Astrazeneca, Sanofi, Janssen Pharmaceuticals, Biomérieux Sa, Ge Healthcare, Hologic, Koninklijke Philips N.V, Biotheranostics and Exact Sciences among others.
March 2021 Agilent Technologies Inc., entered into a definitive agreement to acquire Resolution Bioscience Inc., a leader in the development and commercialization of next-generation sequencing (NGS)-based precision oncology solutions.
March 2020, Thermo Fisher Scientific entered into a partnership with Janssen Biotech, a part of Johnson & Johnson to develop lung cancer companion diagnostic.
July 2020, AnchorDx, a leading biotechnology company developing novel NGS-based early cancer detection and disease monitoring tests, entered into a multi-year collaboration with the Lung Cancer Initiative at Johnson & Johnson to conduct a lung cancer study.
June 2019, Roche, launched in-vitro lung cancer diagnostic test VENTANA ROS1 (SP384) to target ROS1 positive lung cancer.
The report analyses the lung cancer diagnostic market based on cancer type, diagnostic test, end user and country. Various types of lung cancers covered in the lung cancer diagnostic market are small cell lung cancer and non-small cell lung cancers. By diagnostic test, the market is segmented into the biomarkers test, imaging test, biopsy and others. Based on end users, the market is segmented into the hospital associated labs, independent diagnostic laboratories and cancer research institutes. The report also imparts the impact of COVID-19 on the lung cancer diagnostic market and it founds that the COVID-19 has almost affected every market is healthcare industries positively or negatively. The lung cancer diagnostic market is also experienced somewhat negative impact of COVID-19. As due to lockdown, physicians where treating only emergency cases whereby the other diagnostic procedure where postponed. The lung cancer patients are at higher risk of COVID-19 infections. After the slight relaxation the market is growing at significant rates. The market is get resumed with use of mask and maintaining social distancing as per the government guidelines. The report also analyses the major key players operating in the market.
Why to buy this report
